Search

Your search keyword '"Wöll, Stefan"' showing total 23 results
Start Over Author "Wöll, Stefan"
23 results on '"Wöll, Stefan"'

1. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer

Author

De Sanctis, Francesco, Dusi, Silvia, Caligola, Simone, Anselmi, Cristina, Petrova, Varvara, Rossi, Barbara, Angelini, Gabriele, Erdeljan, Michael, Wöll, Stefan, Schlitter, Anna Melissa, Metzler, Thomas, Steiger, Katja, Borok, Zea, Bailey, Peter, Bauer, Aline, Halin, Cornelia, Boschi, Federico, Giugno, Rosalba, Canè, Stefania, Lawlor, Rita, Corbo, Vincenzo, Scarpa, Aldo, Constantin, Gabriela, Ugel, Stefano, Vascotto, Fulvia, Sahin, Ugur, Türeci, Özlem, and Bronte, Vincenzo

Published
2024
Full Text
View/download PDF

3. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

Author

Bähr-Mahmud, Hayat, primary, Ellinghaus, Ursula, additional, Stadler, Christiane R., additional, Fischer, Leyla, additional, Lindemann, Claudia, additional, Chaturvedi, Anuhar, additional, Diekmann, Jan, additional, Wöll, Stefan, additional, Biermann, Imke, additional, Hebich, Bernhard, additional, Scharf, Caroline, additional, Siefke, Manuela, additional, Roth, Alexandra S., additional, Rao, Martin, additional, Brettschneider, Kerstin, additional, Ewen, Eva-Maria, additional, Şahin, Uğur, additional, and Türeci, Özlem, additional

Published
2023
Full Text
View/download PDF

8. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

Author

Reinhard, Katharina, primary, Rengstl, Benjamin, additional, Oehm, Petra, additional, Michel, Kristina, additional, Billmeier, Arne, additional, Hayduk, Nina, additional, Klein, Oliver, additional, Kuna, Kathrin, additional, Ouchan, Yasmina, additional, Wöll, Stefan, additional, Christ, Elmar, additional, Weber, David, additional, Suchan, Martin, additional, Bukur, Thomas, additional, Birtel, Matthias, additional, Jahndel, Veronika, additional, Mroz, Karolina, additional, Hobohm, Kathleen, additional, Kranz, Lena, additional, Diken, Mustafa, additional, Kühlcke, Klaus, additional, Türeci, Özlem, additional, and Sahin, Ugur, additional

Published
2020
Full Text
View/download PDF

17. Abstract A37: Ectopic claudin 6 and 18.2 expression as potential treatment target in non-small cell lung cancer.

Author

Mattsson, Johanna SM, primary, Micke, Patrick, additional, Edlund, Karolina, additional, Lohr, Miriam, additional, Jirström, Karin, additional, Berglund, Anders, additional, Botling, Johan, additional, Rahnenfuehrer, Jörg, additional, Marincevic, Millaray, additional, Pontén, Fredrik, additional, Ekman, Simon, additional, Hengstler, Jan G., additional, Wöll, Stefan, additional, Sahin, Ugur, additional, and Türeci, Özlem, additional

Published
2014
Full Text
View/download PDF

23. Characterization of zolbetuximab in pancreatic cancer models.

Author

Türeci, Ӧzlem, Mitnacht-Kraus, Rita, Wöll, Stefan, Yamada, Tomohiro, and Sahin, Ugur

Subjects
EPITHELIUM, CELL membranes, PANCREATIC cancer, ANTIBODY-dependent cell cytotoxicity, GASTRIC mucosa
Abstract

In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell polarity lead to cell surface exposure of CLDN18.2 epitopes. Moreover, CLDN18.2 is aberrantly expressed in malignancies of several other organs, such as pancreatic cancer (PC). A monoclonal antibody, zolbetuximab (formerly known as IMAB362), has been generated against CLDN18.2. In a phase 2 clinical trial (FAST: NCT01630083), zolbetuximab in conjunction with chemotherapy prolonged overall and progression-free survival over chemotherapy alone and improved quality of life. In this study, the mechanism of action and antitumor activity of zolbetuximab were investigated using nonclinical PC models. Zolbetuximab bound specifically and with strong affinity to human PC cells that expressed CLDN18.2 on the cell surface. In ex vivo systems using immune effector cells and serum from healthy donors, zolbetuximab induced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), resulting in the lysis of cultured human PC cells. The amplitude of ADCC and CDC directly correlated with cell surface CLDN18.2 levels. The chemotherapeutic agent gemcitabine upregulated CLDN18.2 expression in cultured human PC cells and enhanced zolbetuximab-induced ADCC. In mouse xenograft tumors derived from human PC cell lines, including gemcitabine-refractory ones, zolbetuximab slowed tumor growth, benefited survival, and attenuated metastases development. The results presented here validate CLDN18.2 as a targetable biomarker in PC and support extension of the clinical development of zolbetuximab to patients with CLDN18.2-expressing PC. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results